Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sulfoaluminium
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Sulfoaluminium, as referenced in the clinical trial context, appears to be an aluminum-containing compound used for gastrointestinal protection, likely functioning similarly to sucralfate. It is administered as a suspension gel to cover ulcer surfaces, forming a protective barrier against gastric acid, pepsin, and bile acids. This action helps in the treatment of artificial ulcers, such as those occurring after gastric endoscopic submucosal dissection (ESD). The drug is being investigated for its efficacy in treating early gastric cancer, specifically in the context of post-ESD ulcers.
- Other names
- sulfoaluminium suspension gel
Beyond the preview
Go deeper on sulfoaluminium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sulfoaluminium.